COMMUNIQUÉS West-GlobeNewswire

-
Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.
17/09/2024 -
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
17/09/2024 -
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
17/09/2024 -
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology
17/09/2024 -
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
17/09/2024 -
Elicio Therapeutics Reports Inducement Grants
17/09/2024 -
Employer Direct Healthcare Becomes Lantern; Adds New Infusion Offering, and Hires New Clinical Leadership
17/09/2024 -
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
17/09/2024 -
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
17/09/2024 -
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
17/09/2024 -
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
16/09/2024 -
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
16/09/2024 -
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/09/2024 -
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
16/09/2024 -
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
16/09/2024 -
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/09/2024 -
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16/09/2024 -
Galapagos receives transparency notification from EcoR1 Capital
16/09/2024 -
ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium
16/09/2024
Pages